Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?

If so, how long are they on degarelix before the switch?

Answer from: Medical Oncologist at Community Practice

I do not believe that there is a major differential in cardiotoxicity between LHRH antagonists and agonists. The key issue is metabolic syndrome associated with long-term androgen deprivation. Randomized trials have not shown convincing evidence of a difference in cardiotoxicity between agonists and...

Comments

Medical Oncologist at Duke University School of Medicine
I agree which is why we are conducting a randomize...

Radiation Oncologist at American Cancer Center
Good information

Radiation Oncologist at Sutter Health Sacramento
I understand the PRONOUNCE trial, comparing Leupro...

Medical Oncologist at Veterans Administration Health Care Center
I suggest that you reread the trial and consider w...

Medical Oncologist at Stanford School of Medicine
Do you give run-in of peripheral blockade for all ...

Medical Oncologist at University of Mississippi Medical Center
No. My general approach to peripheral blockade for...

Medical Oncologist at Veterans Administration Health Care Center
I usually use a run-in period with a peripheral bl...

Answer from: Radiation Oncologist at Academic Institution

Regardless of the cardiac history, degarelix if covered by insurance because of the ease of discontinuing the ADT. Otherwise leuprolide or equivalent.

Please select the option that best describes you:

Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?

Related Questions